Sanofi partners with miRecule to develop ARC
On October 4, miRecule announced that it has entered into a strategic cooperation and exclusive license agreement with Sanofi to accelerate the development of “best-in-class”
On October 4, miRecule announced that it has entered into a strategic cooperation and exclusive license agreement with Sanofi to accelerate the development of “best-in-class”
On August 17, Atomwise announced that it has entered into a strategic and exclusive research collaboration with Sanofi to leverage its AtomNet® platform for computational
PARIS, August 17, 2022. Sanofi is discontinuing the global clinical development program of amcenestrant, an investigational oral selective estrogen receptor degrader (SERD). The decision is